To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Alnylam Signs Licensing Agreement with GeneDesign
Alnylam Pharmaceuticals, Inc. and GeneDesign, Inc. announced that Alnylam has granted GeneDesign a non-exclusive license to provide RNAi research products and services under the Kreutzer-Limmer patent family. This patent family, owned exclusively by Alnylam, covers small interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells.
"Obtaining a license to the Kreutzer-Limmer patent estate allows us to augment our RNAi products, thereby strengthening our position in the life sciences marketplace in Asia," said Kazuhiko Yuyama, President of GeneDesign. "This agreement with Alnylam, a leader in the field of RNAi, reinforces our ability to become a leading supplier of innovative reagent products to the pharmaceutical and research community."
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
